Akero Therapeutics is a clinical stage biopharmaceutical company dedicated to discovering and developing innovative treatments for patients suffering from serious metabolic diseases, particularly those with high unmet medical needs. The company is currently focused on advancing its lead program, efruxifermin (EFX), aimed at providing a new treatment for metabolic dysfunction-associated steatohepatitis (MASH). With a team of problem solvers and a culture that encourages collaboration and learning, Akero Therapeutics strives to inspire its employees to contribute their best ideas and efforts towards improving patient outcomes.